---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-24-004310"
form_type: "8-K"
ticker: "NXL"
cik: "0001527352"
company_name: "Nexalin Technology, Inc."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:53:08.147808+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nexalin Gen-2 neurostimulation device approved by Brazilian regulator Anvisa

## Summary
- Anvisa approved Nexalin's Gen-2 15 mA neurostimulation device for sale in Brazil.
- This is Nexalin's second regulatory approval outside China in 2024.
- Brazil has >215M population, >35M with mental health disorders; 9th largest economy.
- CEO says approval is springboard into other South American markets; distributor talks underway.

## SEC filing metadata
- accession: 0001829126-24-004310
- form_type: 8-K
- ticker: NXL
- cik: 0001527352
- company_name: Nexalin Technology, Inc.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527352/000182912624004310/0001829126-24-004310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527352/000182912624004310/nexalintech_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-24-004310
- JSON: https://secwatch.observer/filing/0001829126-24-004310.json
- Plain text: https://secwatch.observer/filing/0001829126-24-004310.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.